Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 1082-1091

  Friso, A ^a   Tomanin, R ^a   Salvalaio, M ^a   Scarpa, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Genistein; Glycosaminoglycan; Hunter syndrome; MPSII mouse model; Mucopolysaccharidosis

Indexed keywords

GENISTEIN; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BRAIN; CONTROLLED STUDY; GENE DELETION; HEART; HISTOCHEMISTRY; HUNTER SYNDROME; IN VIVO STUDY; KIDNEY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TISSUE LEVEL; URINE LEVEL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENISTEIN; GLYCOSAMINOGLYCANS; IDURONATE SULFATASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS II; PHYTOESTROGENS;

EID: 77949343015     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00565.x     Document Type: Article

References (39)

1. Akiyama T, Ishida J, Nakagawa S, Ogawara H,Watanabe S, Itoh N et al. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd Edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM (2008). Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99: 475-484.
4. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaria M et al. (2009). The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med 234: 713-725.
5. Bjornsson S (1993). Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal Biochem 210: 282-291.
6. Cardone M, Polito VA, Pepe S, Mann L, D'Azzo A, Auricchio A et al. (2006). Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 15: 1225-1236.
7. D'Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F et al. (2009). Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebocontrolled study. Menopause 16: 320-328.
8. Dire DJ,Wilkinson JA (1987). Acute exposure to rhodamine B. J Toxicol Clin Toxicol 25: 603-607.
9. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA (2006). Positive effect of dietary soy in ESRD patients with systemic inflammation - correlation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol Dial Transplant 21: 2239-2246.
10. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, Valentine JL et al. (2004). Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 48: 160-170.
11. Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M et al. (2005). Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 7: 1482-1491.
12. Friso A, Tomanin R, Zanetti A, Mennuni C, Calvaruso F, La Monica N et al. (2008). Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS). Biochim Biophys Acta 1782: 574-580.
13. Fu H, Kang L, Jennings JS, Moy SS, Perez A, DiRosario J et al. (2007). Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 14: 1065-1077.
14. Garcia AR, Pan J, Lamsa JC, Muenzer J (2007). The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30: 924-934.
15. Gu Y, Zhu CF, Iwamoto H, Chen JS (2005). Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol 11: 6512-6517.
16. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009). Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16: 26.
17. de Jong JG, Wevers RA, Liebrand-van Sambeek R (1992). Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 38: 803-807.
18. Kim H, Peterson TG, Barnes S (1998). Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68: 1418S-1425S.
19. Liu LX, Chen WF, Xie JX, Wong MS (2008). Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res 60: 156-161.
20. McClain RM, Wolz E, Davidovich A, Pfannkuch F, Bausch J (2005). Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol 43: 1461-1482.
21. McClain RM, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J (2006). Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 44: 56-80.
22. Myltic W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W et al. (2003). Lack of significant toxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77: 875-882.
23. Neufeld EF, Muenzer J (2001). The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs R, Kinzler KW (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill Professional Publishing: New York, pp. 3421-3452.
24. Nikitovic D, Tsatsakis AM, Karamanos NK, Tzanakakis GN (2003). The effects of genistein on the synthesis and distribution of glycosaminoglycans/ proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res 23: 459-464.
25. Penar PL, Khoshyomn S, Bhushan A, Tritton TR (1997). Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 40: 141-151.
26. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A et al. (2006). Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expressiontargeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14: 846-852.
27. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymanska A, Liberek A, Maryniak A, Malinowska M et al. (2008). Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 69: 166-179.
28. Pisano MM, Greene RM (1987). Epidermal growth factor potentiates the induction of ornithine decarboxylase activity by prostaglandins in embryonic palate mesenchymal cells: effects on cell proliferation and glycosaminoglycan synthesis. Dev Biol 122: 419-431.
29. Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006). Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60: 309-314.
30. Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S (2007). Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92: 115-121.
31. Tirone E, D'Alessandris C, Hascall VC, Siracusa G, Salustri A (1997). Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1). J Biol Chem 272: 4787-4794.
32. Tomatsu S, Montaño AM, Ohashi A, Gutierres MA, Oikawa H, Oguma T et al. (2007). Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 17: 815-824.
33. Tsai TH (2005). Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 1073: 317-322.
34. Urayama A, Grubb JH, Sly WS, Banks WA (2004). Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci USA 101: 12658-12663.
35. Urayama A, Grubb JH, Banks WA, Sly WS (2007). Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc Natl Acad Sci USA 104: 12873-12878.
36. Urayama A, Grubb JH, Sly WS, Banks WA (2008). Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther 16: 1261-1266.
37. Vera R, Sanchez M, Galisteo M, Villar IC, Jimenez R, Zarzuelo A et al. (2007). Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin Sci (Lond) 112: 183-191.
38. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E et al. (2005). Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102: 14777-14782.
39. Wang ZL, Sun JY, Wang DN, Xie YH, Wang SW, Zhao WM (2006). Pharmacological studies of the large-scaled purified genistein from Huaijiao (Sophora japonica-Leguminosae) on anti-osteoporosis. Phytomedicine 13: 718-723.